Working Group Co-Chairs:  Hank Riordan PhD, Steven Potkin MD

Updates will be provided on qualitative grading data presented at the Autumn Conference session as well as a review of the quantitative data, with a discussion on best method for publishing both the qualitative and quantitative data.

Group will then discuss next steps, whether to remain within schizophrenia(e.g. focus on biomarkers other than imaging) or to continue to examine imaging or another biomarker in a different therapeutic area like AD, PD, neuropathic pain etc. that might be more closely aligned with upcoming meeting topics, and finally, develop  a long range (>2 years) strategy for the group.